# Human proof matters — “Research Peptide Fundamentals research peptides” > Proof first — Research Peptide Fundamentals research peptides — Research Peptide Fundamentals research peptides: human proof varies among four peptides. Benefits, possible harm, and missing answers for your care. **TRUE COST PEPTIDE / FOUR PEPTIDES EXPLAINED** What makes a peptide claim worth believing? Studies in people need to show better health and track harm. Animal findings alone can’t answer your care questions. ### [CJC-1295](/cjc-1295) Early tests in people found hormones raised for days. The two versions differ. Neither has approval for treating people. ### [BPC-157](/bpc-157) A 15-amino-acid peptide, made of small chemical pieces that join together to make proteins. Most findings concern animals; human healing remains unproven. ### [Semaglutide](/semaglutide) Semaglutide copies GLP-1, a hormone released after eating. This approved medicine has large studies of weight, kidney health, and heart trouble. ### [Tesamorelin](/tesamorelin) Tesamorelin has approval for unusual belly-fat buildup during HIV care. Those findings don’t show a general weight-loss treatment. ## The short version: human comparisons give the clearest answers Which kind of test can answer your question about benefit? Human comparisons give firmer answers about human care than animal findings. First, researchers check that the substance contains what was intended. Animal work may then find effects worth testing in people. Human studies compare health changes, possible harms, and how long benefits last. Each kind of testing costs money and takes skilled work. A striking result still leaves other questions to be answered. Early CJC-1295 tests found higher hormones, not proven lasting health gains. Most BPC-157 findings concern animals, with testing in people still scarce. Semaglutide has large studies of weight and serious health problems. Tesamorelin has approval for one unusual problem with body fat. That approval doesn't show benefits for every kind of belly fat. Your claim needs a study that measured the claimed benefit. A hormone rise alone cannot tell whether someone felt better. ## A label cannot show what a bottle contains Researchers tested a seized product from an investigation into banned sports drugs [2]. The label described a hormone type without clearly naming the substance inside. Tests found CJC-1295 inside; the label alone couldn't show the contents. Researchers need the intended substance before they can study benefits. Otherwise, an apparent effect may come from something else entirely. For you, uncertain contents mean uncertain claims about benefits and harm. Early BPC-157 tests found growth of new blood vessels [11]. Animal tests also found that the substance broke down quickly [10]. Those tests concerned animals and cells kept alive within a laboratory dish. Faster recovery in injured patients was not tested. New vessels might help repair, but that possibility needs human testing. Studies of people compare groups receiving different kinds of care. Staff check health changes and unwanted effects throughout the study. Large semaglutide trials measured weight, kidney disease, and heart problems [14][15][16]. Tesamorelin studies tested unusual fat buildup during care for HIV [18][19]. HIV reduces protection against infection by harming the immune system. Each result applies most directly to the people actually studied. Missing human testing leaves a gap that animal results cannot fill. ## Peptides can have very different standing as medicines Amino acids are small chemical pieces that join together to make proteins. Peptides contain fewer of those joined pieces than most proteins. Some peptides let one body part send messages to another. Changes made in a laboratory can slow a peptide's breakdown. Other changes help the peptide stay attached to blood proteins. CJC-1295 and tesamorelin copy a hormone whose message prompts release of growth hormone. Semaglutide copies GLP-1, a hormone released after food is eaten. BPC-157 copies part of a substance described in stomach fluid. The words **research peptide** do not show approval or reliable benefits. Semaglutide has approval for prescription treatment of certain health problems. Tesamorelin's approval concerns a much narrower problem with body fat. CJC-1295 and BPC-157 have no approved use for treating people. These differences carry more weight than the shared name peptide. Early tests can show an effect without showing better health. For you, the tested substance and the measured health change matter. The group receiving other care matters just as much. A shared name cannot give these substances the same proof. ## The four substances differ most in testing with people Semaglutide stands out here for its much larger studies with patients. The other three have useful findings with much narrower reach. Each result needs the limits that go with that result. - [**CJC-1295**](/cjc-1295) raised hormones for days in early human tests. A review discusses related hormone treatments and further research [1]. Release still occurred in the gland's usual bursts [4][5]. Those studies left lasting health benefits unproven. - [**BPC-157**](/bpc-157) has mainly tests with animals or dishes of cells. Human studies were scarce and small in the reviewed research [9]. Healing claims lacked large trials with patients in that review. - [**Semaglutide**](/semaglutide) has large trials that measured actual health changes. Researchers compared weight, kidney problems, and serious heart problems [14][15][16]. The patients had certain conditions, so the findings aren't universal. - [**Tesamorelin**](/tesamorelin) reduced fat surrounding organs during care for HIV. Studies compared groups and brought their results together [18][19][20]. Approval covers that unusual fat problem, not everyone's extra weight. The [comparison](/compare) explains why those differences matter for a health claim. The [study list](/references) links each finding to its published study. Counting papers alone won't tell you how reliable a benefit is. ## A health claim needs a study of that health change Large trials can answer questions that animal work leaves open. Even a large trial concerns the patients who actually joined. A dish of cells can show what happened inside those cells. Animal tests show what changed within the animals tested. Small human tests may measure hormones without measuring improved health. Group comparisons help show whether a treatment caused a benefit. Other teams can repeat the testing to check the earlier result. Longer trials can reveal harm that took months to appear. Your health question needs testing that actually addresses that question. People also describe trying peptides experimentally outside the cited trials. Their accounts don't show whether a doctor supervised that use. Those reports aren't findings checked against another group receiving different treatment. Such reports may suggest questions, but cannot settle cause or safety. Animal improvements also cannot count as proof that people improved. Even an approved medicine has limits on its tested uses. You won't find products or personal treatment plans in this guide. Knowing why an effect might happen cannot replace a human result. --- True Cost Peptide is an independent evidence-lifecycle digest that audits what peptide claims cost to prove; it is neither a store nor medical advice.